NatureRevClinOncol (@natrevclinoncol) 's Twitter Profile
NatureRevClinOncol

@natrevclinoncol

The latest clinical diagnostic, treatment & personalized medicine advances & more from Nature Reviews Clinical Oncology, a reviews journal.

ID: 347276297

linkhttp://www.nature.com/nrclinonc/index.html calendar_today02-08-2011 15:04:10

14,14K Tweet

41,41K Takipçi

244 Takip Edilen

NatureRevClinOncol (@natrevclinoncol) 's Twitter Profile Photo
NatureRevClinOncol
@natrevclinoncol

a year ago

Yesterday, the FDA granted accelerated approval to zanubrutinib combined with obinutuzumab for R/R follicular lymphoma after ≥2 lines of therapy, based on an ORR of 69% vs 46% with obinutuzumab alone; the mDoR was NR (69% at 18 months) vs 14.0 months: fda.gov/drugs/resource…